![]() ![]() DocuSign has seen a sustained rise in demand since Q1 of this year that management expects to continue. Subscription revenue made up roughly 95% of revenue in the quarter. Total revenue increased 45% to $342.2 million year-over-year (YoY) and international revenue grew 65%, making up just under one-fifth of revenue. It also has 18 of the top 20 global pharmaceutical companies and 10 of the top 15 global financial companies. To put this into context, DocuSign added more customers in the first half of this year than in the whole of 2019. It has millions of users worldwide and 749,000 paying customers as of fiscal Q2, 2021 an increase of 88,000 on the prior quarter. Its core business revolves around e-signatures, unlike its biggest rival, Adobe (NASDAQ: ADBE).ĭocuSign boasts an impressive market share of roughly 70%. The shift to digital has accelerated the use of e-signatures, but which is a better investment? DocuSign: The Bull and Bear CaseĭocuSign (NASDAQ: DOCU) is the leader in the e-signature market, having gone public in 2018, and its stock is up over 200% year-to-date (YTD). One would be forgiven for overlooking e-signatures as a high growth area and failing to recognize the potential of an investment in this rapidly expanding space. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |